J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group

J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD